Agendia

IRVINE, Calif., May 23, 2013 /PRNewswire/ -- More than half of women diagnosed with early stage breast cancer may not benefit from chemotherapy and still have excellent outcomes. To educate women, Agendia, Inc. has announced the launch of one of the largest sources of online consumer ... read more

IRVINE, Calif., May 2, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone. The MammaPrint test analyzes 70 key genes and accurately determines which ... read more

The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat the disease, according to a newly published study. ... read more

IRVINE, Calif. and AMSTERDAM, Jan. 25, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the addition of Dr. Neil M. Barth as its Chief Medical Officer. In this role, Dr. Barth will translate complex laboratory science and personalized medicine diagnostics into ... read more

IRVINE, Calif. and AMSTERDAM, Nov. 27, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is ... read more